Moxifloxacin treatment of acute exacerbation of chronic obstructive pulmonary disease Clinical Evaluation.doc

 PAGE \* MERGEFORMAT 12 Moxifloxacin treatment of acute exacerbation of chronic obstructive pulmonary disease Clinical Evaluation [Abstract] Objective To evaluate the moxifloxacin treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD effect. Methods 60 patients with AECOPD were randomly divided Rumoxisha Star sequential therapy group (30 cases and the control group (30 patients, sequential therapy group received intravenous infusion of moxifloxacin 0.4, 1 times / day, 3 to 5 days to oral moxifloxacin 0.4, 1 time / day total course of treatment 7 to 10 days in the control group received intravenous infusion of moxifloxacin 0.4, 1 / day total course of treatment 7 to 10 days, respectively, were observed in the clinical total effective rate, bacterial clearance, adverse reaction rates, and cost-effectiveness analysis. Results of sequential treatment group and control group clinical total effective rate was 83.33 % and 90.00%, the bacterial clearance rates were 83.33% and 81.82%, the two groups showed no significant difference (P allgt; 0.05, two groups of adverse reaction rates were 6.67%, The mean hospital stay was 9.43 + -2.49 days and 12.37 + -5.45 days, average hospital costs were 4622.07 + 5928.23 + -2984.87 -1633.77 RMB yuan and the two groups sequential group shorter hospitalization time, cost less (P lt;0.05 or 0.01. Conclusion The efficacy of moxifloxacin in treatment of AECOPD significant adverse reactions are mild, but the sequential therapy can reduce patient care costs, shorter hospital stay, cost / effectiveness ratio is better than full intravenous administration, should the preferred treatment for AECOPD. [Keywords:] moxifloxacin sequential therapy, acute exacerbation of chronic obstructive pulmonary disease Acute exacerbation of chronic obstructive pulmonary disease (acute exacerbations of COPD, AECOPD mostly caused by bacterial infection, use of antibiotics for primary treatment, but prevalence of inappropriate